Naomi Kamau
Clinical Trial Manager
Naomi is a Clinical Trial Manager within the Nuffield Department of Primary Care Health, University of Oxford, currently managing the DURATION UTI trial. She joined the Clinical Trials Unit in October 2022 as a Trial Manager for DURATION UTI, a study that is evaluating the shortest antibiotic treatment duration needed to effectively treat urinary tract infections (UTI) in women.
Before joining the department, Naomi worked on multiple vaccine trials as a Clinical Trial Coordinator at the Kenya Medical Research Institute's Centre for Geographic Medicine Research Coast (KEMRI-CGMRC) at Kilifi, Kenya.
As a Trial Coordinator, she managed several multicentre trials within Kenya and in Uganda sponsored by the University of Oxford and MSF Epicentre in France. Here, her roles involved the delivery of trials within time, budget, and scope, stakeholder engagement, and ensuring delivery of quality study results.
These trials include A phase 1b/II ChAdOx1 nCoV-19 Vaccine trial evaluating the safety, immunogenicity, and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya; two Phase IV Yellow Fever vaccine studies evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda namely YEFE and NIFTY; and a Phase I Rift Valley Fever Virus (RVFV) vaccine trial (ChAdOx1 RVF) evaluating the safety and efficacy of the new Rift Valley Fever vaccine.